MedTrace Logo

Safety and Efficacy of ABT-510 in Subjects With Advanced Renal Cell Carcinoma

NCT00073125 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 103

Last updated 2007-08-15

No results posted yet for this study

Summary

The primary objective of this study is to assess the safety and efficacy of ABT-510 in subjects with advanced renal cell carcinoma.

Conditions

  • Carcinoma, Renal Cell

Interventions

DRUG

ABT-510/Thrombospondin-1 mimetic

Sponsors & Collaborators

Principal Investigators

  • Rod Humerickhouse, MD · Abbott

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-05-31

Countries

  • United States
  • Netherlands

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00073125 on ClinicalTrials.gov